Explain the resolution criteria for the Eli Lilly (LLY) earnings market in the simplest terms, specifically the win condition of non-GAAP EPS being greater than $7.00 and how the fallback mechanism using SeekingAlpha data works.

AI-powered analysis for: Explain the resolution criteria for the Eli Lilly (LLY) earnings market in the simplest terms, specifically the win condition of non-GAAP EPS being greater than $7.00 and how the fallback mechanism using SeekingAlpha data works.. Get detailed insights and real-time data on PolyPredict AI.

Search for the latest sentiment from Wall Street analysts and financial KOLs regarding Eli Lilly's (LLY) April 2026 earnings, summarizing the core bullish and bearish arguments on whether the EPS will beat the $7.0 estimate.

AI-powered analysis for: Search for the latest sentiment from Wall Street analysts and financial KOLs regarding Eli Lilly's (LLY) April 2026 earnings, summarizing the core bullish and bearish arguments on whether the EPS will beat the $7.0 estimate.. Get detailed insights and real-time data on PolyPredict AI.

Given that this market is estimated to resolve on April 30, 2026, calculate the opportunity cost of locking capital in the Eli Lilly (LLY) earnings market, and evaluate whether the potential excess return is worth it compared to risk-free yields in DeFi protocols.

AI-powered analysis for: Given that this market is estimated to resolve on April 30, 2026, calculate the opportunity cost of locking capital in the Eli Lilly (LLY) earnings market, and evaluate whether the potential excess return is worth it compared to risk-free yields in DeFi protocols.. Get detailed insights and real-time data on PolyPredict AI.

Will Eli Lilly and Co (LLY) beat quarterly earnings?

Finance|$6 Vol|

11 days 22 hrs

Will Eli Lilly and Co (LLY) beat quarterly earnings? - AI Mispricing Alert

AI Signal Dashboard

Last updated: 04.17 23:08

Top Undervalued

+5¢

(Yes)

Will Eli Lilly and Co (LLY) beat quarterly earnings? AI analysis: • +5¢ undervalued • Live Prediction Market fair value & mispricing alerts.

Undervalued Options Insights:

Eli Lilly (LLY) is scheduled to release earnings with a Wall Street consensus non-GAAP EPS estimate ...

🔓 Unlock Mispricing Insights (Pro)

All Outcomes

Market Price

AI Fair Value

Value Edge

YesNo

50¢

55¢

45¢

+5¢

0¢

⚠️ Risk Warning: Live data may lag! Prices can shift instantly due to news or low liquidity. Before trading, use AI Chat for [Live Recalculate], [Check Liquidity], [Trollbox Radar], or review [Fair Value Logic] to verify.

Hedging

NVO

LLY

Eli Lilly (LLY) has become one of the world's most valuable pharmaceutical companies due to the massive success of its GLP-1 weight loss and diabetes drugs. An earnings beat or miss will directly and significantly impact LLY's stock price (impact score 4). Additionally, its main competitor Novo Nordisk (NVO) will likely experience strong sympathy moves (impact score 3). Due to its massive market cap, it will also have a minor impact on the S&P 500 healthcare sector and the broader market.